BioNexus Gene Lab Corp. BGLC · SEC Filings

website

BioNexus Gene Lab Corp. (BGLC), established in 2017 and headquartered in Kuala Lumpur, Malaysia, con...

Price0.8923

Market Cap2.61 M

Float2.41 M

CountryMY

SectorIndustrials

ExchangeNASDAQ

Overview Filings Insights Dilution News Transcripts

Search in Documents

Open in Studio Login

TYPE

HEADLINE

FILED AT

TYPE

HEADLINE

FILED AT

TYPE

HEADLINE

FILED AT

TYPE

HEADLINE

FILED AT

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 14, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 15, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Apr 14, 2026

NT 10-K

Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405

Mar 31, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 14, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 18, 2025

News

TYPE

HEADLINE

FILED AT

8-K

BioNexus Gene Lab to License CogniAI Platform from Ruanyun Edai Technology to Build AI Applications for Malaysian Healthcare

Oct 7, 2026

8-K

BioNexus Advances VitaGuard™ Southeast Asia Rollout Following China Working Visit

Jul 28, 2026

8-K

BioNexus Gene Lab Corp. Advocates for Malaysia–China Biotechnology Co-Development Partnership

Jun 5, 2026

8-K

BioNexus Gene Lab Corp. Appoints Dr. Muthu Meyyappan as Chief Commercial Officer of Fidelion Diagnostics

Mar 17, 2026

8-K

BioNexus Gene Lab Completes Governance Restructuring of Subsidiary Chemrex; Appoints Matthew Barsing as Chairman

Feb 23, 2026

8-K

BioNexus Launches VitaGuard™ MRD Infrastructure Deployment in Southeast Asia

Feb 3, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B4

OFFERING | Shares amount: 1,250,000 | Share price: $4.00 | Offering amount: $5,000,000.00

Jul 21, 2023

Registrations

TYPE

HEADLINE

FILED AT

S-3

November 2025 SHELF & ATM | Float: 1,796,597 | Amount sold to date: $0

Nov 7, 2025

8-A12B

Registration

Jul 19, 2023

S-1/A

INITIAL REGISTRATION FOR OFFERING EFFECTIVE

Jul 14, 2023

S-1/A

INITIAL REGISTRATION FOR OFFERING EFFECTIVE

Jul 3, 2023

S-1/A

INITIAL REGISTRATION FOR OFFERING EFFECTIVE

May 8, 2023

S-1

] Shares of Common Stock EFFECTIVE

Feb 14, 2023

Proxies

TYPE

HEADLINE

FILED AT

Ownerships

TYPE

HEADLINE

FILED AT

SCHEDULE 13G

FIDELION DIAGNOSTICS PTE. LTD. (Filed by)

Oct 22, 2026

SCHEDULE 13D

Tan Lee Su-Leng (Filed by)

Aug 14, 2026

Tan Lee Su-Leng (Reporting)

Aug 14, 2026

Yap Chee Keong (Reporting)

Aug 14, 2026

Bin Abdul Hamid Muhammad Azrul (Reporting)

Aug 14, 2026

Chong Set Fui (Reporting)

Aug 14, 2026

Other

TYPE

HEADLINE

FILED AT